We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Make or break

24 August 2016 By Robert Cyran

Three U.S. senators are slamming the $24 bln drug firm for jacking up the cost of its anaphylaxis treatment more than fivefold since 2008. An investigation could limit Mylan’s pricing power on the product that has provided much of its growth and spread to the firm’s other drugs.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)